Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611287 | 0.96 | SIRT2 (0.32) | SIRT2SIRT1SIRT3 | |
| SCHEMBL13611124 | 0.91 | SIRT2 (0.32) | SIRT2SIRT1SIRT3 | |
| SCHEMBL13611169 | 0.91 | FURIN (0.31) | — | |
| SCHEMBL13499207 | 0.91 | SIRT2 (0.32) | SIRT2SIRT1SIRT3 | |
| SCHEMBL12236104 | 0.91 | SIRT2 (0.32) | SIRT2SIRT1SIRT3 | |
| SCHEMBL12236129 | 0.91 | SIRT2 (0.32) | SIRT2SIRT1SIRT3 | |
| SCHEMBL13611181 | 0.91 | SIRT2 (0.32) | SIRT2SIRT1SIRT3 | |
| SCHEMBL13611182 | 0.87 | SIRT2 (0.33) | SIRT2SIRT1SIRT3 | |
| SCHEMBL12236156 | 0.86 | ALB (0.34) | — | |
| SCHEMBL13435495 | 0.86 | PRCP (0.43) | SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087205-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | PALATIN TECHNOLOGIES INC (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160354443-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | PALATIN TECHNOLOGIES INC (US) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087205-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | NPR1, NPR3, NPPA | SIRT2 4373/4885SIRT1 4383/4885SIRT3 4573/4885 |
| US-20160354443-A1 | Replacement Therapy for Natriuretic Peptide Deficiencies | NPR1, NPR3, NPPA | SIRT2 4373/4885SIRT1 4383/4885SIRT3 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.